Irinotecan and Colon Cancer Resistance
Author Information
Author(s): Basseville Agnes, Preisser Laurence, de Carné Trécesson Sophie, Boisdron-Celle Michèle, Gamelin Erick, Coqueret Olivier, Morel Alain
Primary Institution: Cancer Center Paul Papin, INSERM U892 / University of Angers
Hypothesis
The study investigates the role of the steroid and xenobiotic receptor (SXR) in the induction of drug resistance in colon cancer cells.
Conclusion
The SXR pathway is involved in irinotecan resistance in colon cancer cell lines through the upregulation of detoxification genes.
Supporting Evidence
- SXR is activated in response to SN-38 treatment in colon cancer cell lines.
- SXR translocates to the nucleus and binds to the CYP3A4 gene promoter.
- Cells overexpressing SXR show reduced sensitivity to irinotecan treatment.
Takeaway
This study shows that a protein called SXR helps colon cancer cells resist a drug called irinotecan by turning on genes that detoxify the drug.
Methodology
The study used human colon cancer cell lines to investigate the activation of SXR and its effects on detoxification gene expression following treatment with irinotecan's active metabolite, SN-38.
Limitations
The study primarily focuses on specific cell lines and may not fully represent the complexity of drug resistance in all colon cancer cases.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website